Five Prime Therapeutics Inc (FPRX) SEC Filing 8-K Material Event for the period ending Monday, June 24, 2019

Five Prime Therapeutics Inc

CIK: 1552493 Ticker: FPRX

View differences made from one to another to evaluate Five Prime Therapeutics Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Five Prime Therapeutics Inc.


Assess how Five Prime Therapeutics Inc's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Five Prime Therapeutics Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools
Ticker: FPRX
CIK: 1175505
Form Type: 8-K Corporate News
Accession Number: 0001193125-19-186002
Submitted to the SEC: Fri Jun 28 2019 4:07:55 PM EST
Accepted by the SEC: Fri Jun 28 2019
Period: Monday, June 24, 2019
Industry: Pharmaceutical Preparations
  1. Event for Officers

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: